|
|
Blood, 15 April 2007, Vol. 109, No. 8, pp. 3161-3172.
Prepublished online as a Blood First Edition Paper on November 16, 2006; DOI 10.1182/blood-2006-09-003004.
Previous Article | Table of Contents | Next Article 
REVIEW IN TRANSLATIONAL HEMATOLOGY
The cytoprotective protein C pathway
Laurent O. Mosnier1,
Berislav V. Zlokovic2, and
John H. Griffin1
1 Department of Molecular and Experimental Medicine (MEM-180), The Scripps Research Institute, La Jolla, CA;
2 Department of Neurosurgery, University of Rochester, NY
Protein C is best known for its mild deficiency associated with venous thrombosis risk and severe deficiency associated with neonatal purpura fulminans. Activated protein C (APC) anticoagulant activity involves proteolytic inactivation of factors Va and VIIIa, and APC resistance is often caused by factor V Leiden. Less known is the clinical success of APC in reducing mortality in severe sepsis patients (PROWESS trial) that gave impetus to new directions for basic and preclinical research on APC. This review summarizes insights gleaned from recent in vitro and in vivo studies of the direct cytoprotective effects of APC that include beneficial alterations in gene expression profiles, anti-inflammatory actions, antiapoptotic activities, and stabilization of endothelial barriers. APC's cytoprotection requires its receptor, endothelial cell protein C receptor, and protease-activated receptor-1. Because of its pleiotropic activities, APC has potential roles in the treatment of complex disorders, including sepsis, thrombosis, and ischemic stroke. Although much about molecular mechanisms for APC's effects on cells remains unclear, it is clear that APC's structural features mediating anticoagulant actions and related bleeding risks are distinct from those mediating cytoprotective actions, suggesting the possibility of developing APC variants with an improved profile for the ratio of cytoprotective to anticoagulant actions.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. T. Esmon
Dimorphisms in the Membrane-Spanning Domain of EPCR Impact Systemic Coagulation
Arterioscler Thromb Vasc Biol,
November 1, 2009;
29(11):
1712 - 1713.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C McCann and B. N Ames
Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?
Am. J. Clinical Nutrition,
October 1, 2009;
90(4):
889 - 907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Delvaeye and E. M. Conway
Coagulation and innate immune responses: can we view them separately?
Blood,
September 17, 2009;
114(12):
2367 - 2374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Stevens and S. R. Lentz
Countervailing Effects on Atherogenesis and Plaque Stability: A Paradoxical Benefit of Hypercoagulability?
Circulation,
September 1, 2009;
120(9):
722 - 724.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. G. Brooks, W. Trotman, M. P. Wadsworth, D. J. Taatjes, M. F. Evans, F. P. Ittleman, P. W. Callas, C. T. Esmon, and E. G. Bovill
Valves of the deep venous system: an overlooked risk factor
Blood,
August 6, 2009;
114(6):
1276 - 1279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B.-S. Ding, N. Hong, M. Christofidou-Solomidou, C. Gottstein, S. M. Albelda, D. B. Cines, A. B. Fisher, and V. R. Muzykantov
Anchoring Fusion Thrombomodulin to the Endothelial Lumen Protects against Injury-induced Lung Thrombosis and Inflammation
Am. J. Respir. Crit. Care Med.,
August 1, 2009;
180(3):
247 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Sennoun, C. Baron-Menguy, M. Burban, T. Lecompte, R. Andriantsitohaina, D. Henrion, A. Mercat, P. Asfar, B. Levy, and F. Meziani
Recombinant human activated protein C improves endotoxemia-induced endothelial dysfunction: a blood-free model in isolated mouse arteries
Am J Physiol Heart Circ Physiol,
July 1, 2009;
297(1):
H277 - H282.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. O. Mosnier, A. Zampolli, E. J. Kerschen, R. A. Schuepbach, Y. Banerjee, J. A. Fernandez, X. V. Yang, M. Riewald, H. Weiler, Z. M. Ruggeri, et al.
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant
Blood,
June 4, 2009;
113(23):
5970 - 5978.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Tanaka, N. S. Key, and J. H. Levy
Blood Coagulation: Hemostasis and Thrombin Regulation
Anesth. Analg.,
May 1, 2009;
108(5):
1433 - 1446.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Wang, M. Thiyagarajan, N. Chow, I. Singh, H. Guo, T. P. Davis, and B. V. Zlokovic
Differential Neuroprotection and Risk for Bleeding From Activated Protein C With Varying Degrees of Anticoagulant Activity
Stroke,
May 1, 2009;
40(5):
1864 - 1869.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. F. Elphick, P. P. Sarangi, Y.-M. Hyun, J. A. Hollenbaugh, A. Ayala, W. L. Biffl, H.-L. Chung, A. R. Rezaie, J. L. McGrath, D. J. Topham, et al.
Recombinant human activated protein C inhibits integrin-mediated neutrophil migration
Blood,
April 23, 2009;
113(17):
4078 - 4085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Morel, F. Toti, N. Morel, and J.-M. Freyssinet
Microparticles in endothelial cell and vascular homeostasis: are they really noxious?
Haematologica,
March 1, 2009;
94(3):
313 - 317.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gupta, B. Gerlitz, M. A. Richardson, C. Bull, D. T. Berg, S. Syed, E. J. Galbreath, B. A. Swanson, B. E. Jones, and B. W. Grinnell
Distinct Functions of Activated Protein C Differentially Attenuate Acute Kidney Injury
J. Am. Soc. Nephrol.,
February 1, 2009;
20(2):
267 - 277.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. V. Yang, Y. Banerjee, J. A. Fernandez, H. Deguchi, X. Xu, L. O. Mosnier, Rolf. T. Urbanus, P. G. de Groot, T. C. White-Adams, O. J. T. McCarty, et al.
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells
PNAS,
January 6, 2009;
106(1):
274 - 279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Thiyagarajan, J. A. Fernandez, S. M. Lane, J. H. Griffin, and B. V. Zlokovic
Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1
J. Neurosci.,
November 26, 2008;
28(48):
12788 - 12797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. K. Mahmoodi, J.-L. P. Brouwer, N. J.G.M. Veeger, and J. van der Meer
Hereditary Deficiency of Protein C or Protein S Confers Increased Risk of Arterial Thromboembolic Events at a Young Age: Results From a Large Family Cohort Study
Circulation,
October 14, 2008;
118(16):
1659 - 1667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Danielyan, K. Ganguly, B.-S. Ding, D. Atochin, S. Zaitsev, J.-C. Murciano, P. L. Huang, S. E. Kasner, D. B. Cines, and V. R. Muzykantov
Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator
Circulation,
September 30, 2008;
118(14):
1442 - 1449.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Medina, S. Navarro, J. Corral, E. Zorio, V. Roldan, A. Estelles, A. Santamaria, F. Marin, J. Rueda, R. M. Bertina, et al.
Endothelial protein C receptor polymorphisms and risk of myocardial infarction
Haematologica,
September 1, 2008;
93(9):
1358 - 1363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Toltl, S. Beaudin, P. C. Liaw, and and the Canadian Critical Care Translational Biolo
Activated Protein C Up-Regulates IL-10 and Inhibits Tissue Factor in Blood Monocytes
J. Immunol.,
August 1, 2008;
181(3):
2165 - 2173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sood, L. Sholl, B. Isermann, M. Zogg, S. R. Coughlin, and H. Weiler
Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin
Blood,
August 1, 2008;
112(3):
585 - 591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bouchama, C. Kunzelmann, M. Dehbi, A. Kwaasi, A. Eldali, F. Zobairi, J.-M. Freyssinet, and D. de Prost
Recombinant Activated Protein C Attenuates Endothelial Injury and Inhibits Procoagulant Microparticles Release in Baboon Heatstroke
Arterioscler Thromb Vasc Biol,
July 1, 2008;
28(7):
1318 - 1325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Dahlback
Advances in understanding pathogenic mechanisms of thrombophilic disorders
Blood,
July 1, 2008;
112(1):
19 - 27.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Richardson, A. Gupta, L. A. O'Brien, D. T. Berg, B. Gerlitz, S. Syed, G. R. Sharma, M. S. Cramer, J. G. Heuer, E. J. Galbreath, et al.
Treatment of Sepsis-Induced Acquired Protein C Deficiency Reverses Angiotensin-Converting Enzyme-2 Inhibition and Decreases Pulmonary Inflammatory Response
J. Pharmacol. Exp. Ther.,
April 1, 2008;
325(1):
17 - 26.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Geiger
Soluble protein C receptor: why?
Blood,
April 1, 2008;
111(7):
3301 - 3302.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Schuepbach, C. Feistritzer, L. F. Brass, and M. Riewald
Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin
Blood,
March 1, 2008;
111(5):
2667 - 2673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. O'Brien, M. A. Richardson, S. F. Mehrbod, D. T. Berg, B. Gerlitz, A. Gupta, and B. W. Grinnell
Activated Protein C Decreases Tumor Necrosis Factor Related Apoptosis-Inducing Ligand by an EPCR- Independent Mechanism Involving Egr-1/Erk-1/2 Activation
Arterioscler Thromb Vasc Biol,
December 1, 2007;
27(12):
2634 - 2641.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. O. Mosnier, X. V. Yang, and J. H. Griffin
Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions
J. Biol. Chem.,
November 9, 2007;
282(45):
33022 - 33033.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Kerschen, J. A. Fernandez, B. C. Cooley, X. V. Yang, R. Sood, L. O. Mosnier, F. J. Castellino, N. Mackman, J. H. Griffin, and H. Weiler
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C
J. Exp. Med.,
October 1, 2007;
204(10):
2439 - 2448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Kowalska, S. A. Mahmud, M. P. Lambert, M. Poncz, and A. Slungaard
Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge
Blood,
September 15, 2007;
110(6):
1903 - 1905.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|